Deferred Federal Income Tax Expense (Benefit) of CERO THERAPEUTICS HOLDINGS, INC. for 09 May 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.
Summary
CERO THERAPEUTICS HOLDINGS, INC. quarterly Deferred Federal Income Tax Expense (Benefit) in USD history and change rate for 09 May 2023.
  • CERO THERAPEUTICS HOLDINGS, INC. Deferred Federal Income Tax Expense (Benefit) for the quarter ending 09 May 2023 was $182,308.
Source SEC data
View on sec.gov
Deferred Federal Income Tax Expense (Benefit), Quarterly (USD)

CERO THERAPEUTICS HOLDINGS, INC. Quarterly Deferred Federal Income Tax Expense (Benefit) (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q1 2023 $182,308 09 May 2023 10-Q 14 Aug 2023 2023 Q2
* An asterisk sign (*) next to the value indicates that the value is likely invalid.